Survey Identifies Worry as a Core Symptom During Multiple Myeloma Treatment
A cross-sectional survey study sought to determine the core symptom experienced by patients with MM while undergoing chemotherapy treatment.
Diagnosis & Disease Information
Eligibility Criteria May Influence Disparity in Multiple Myeloma Trial Enrollment
Blacks and other race subgroups have higher multiple myeloma trial ineligibility rates compared with Whites.
Heart Failure Rates After Carfilzomib Similar in Black and White MM Patients
New research suggests that carfilzomib increases the risk of heart failure in patients with multiple myeloma, but the risk does not appear to vary between Black and White patients.
Prognosis of Multiple Myeloma Has Improved Since 2000
However, multiple myeloma patients still have elevated likelihood of dying from nonmyeloma malignancies, CVDs.
Belantamab Mafodotin Deemed Safe, Effective in Real-World MM Population
Belantamab mafodotin has shown clinical activity and a manageable safety profile in a real-world population of patients with relapsed/refractory multiple myeloma.
Exercise App Appears Supportive, Responsive for Patients With Multiple Myeloma
Researchers sought to determine whether a novel exercise app would be helpful for patients with multiple myeloma.
Motixafortide Plus G-CSF Increases HSPC Numbers for Apheresis Prior to ASCT
A phase 3, randomized study compared motixafortide with placebo to determine safety and efficacy of the drug in the mobilization of CD34+ HSPCs in patients with MM.
Associations Between Cancer and COVID-19 Death “More Substantial” in Women
The risk of in-hospital death from COVID-19 for patients with cancer differs by sex and cancer type, according to a new study.
Molecular Profiling Aids in Determining Which Patients With Multiple Myeloma Will Benefit From Lenalidomide Maintenance
Researchers sought to determine whether genetic markers may indicate a high likelihood of benefitting from lenalidomide maintenance in patents with multiple myeloma who undergo ASCT.
Risk of Early Death Higher in Older Patients With Multiple Myeloma
Multiple myeloma patients aged 70 years or older have a nearly 3-fold higher rate of early death than younger patients, new research suggests.
- Loading...
Loading...
Loading... 
Loading...